Friday 9th October 2020

Have you given your risk of flu a second thought?

Many people are entitled to a free flu jab this year, and you may have received a letter about this. But why is this important and what are the benefits? And is there anyone who should not have the flu vaccine? We have all the answers you need.

Read Article

Friday 2nd October 2020

Joint statement on rise in COVID-19 cases in the UK

Together with our partner organisations of RAIRDA (The Rare Autoimmune Rheumatic Diseases Alliance), we have released a joint statement in response to the recent rise in coronavirus cases. This is regarding the effect of the pandemic on the ongoing, continuing care of people with rare, autoimmune conditions, including scleroderma; as well as the issue of shielding.

Read Article

Tuesday 29th September 2020

SRUK’s co-funded project with World Scleroderma Foundation seeking to improve the Combined Response Index in SSc Score.

An important part of participating in a project such as this is ensuring that you understand how the collected data will be used and why community input is so valuable and fundamentally vital.

Read Article

Thursday 24th September 2020

Exploring Acupuncture

Acupuncture is an alternative treatment that comes from ancient, Chinese medicine. An acupuncturist inserts fine needles upon specific points of the body, with the aim of stimulating and balancing the flow of energy. There is some evidence that acupuncture could help to alleviate the symptoms of both Raynaud’s and scleroderma.

Read Article

Wednesday 26th August 2020

Back To Life - The Psychological Journey Towards a 'New Normal'

Dr. Jo Daniels looks at coping strategies to help in adjusting to the new 'normal' as we resume our daily activities. Based on cognitive behavourial therapy techniques, these simple steps can help us all to feel a little bit more in control as life moves on.

Read Article

Friday 21st August 2020

Findings of nintedanib's safety and tolerability published

A team of researchers based in the USA, UK, Germany, Switzerland and Japan sought to examine the results of the SENSCIS trial to assess the safety and tolerability of nintedanib in people with SSc-ILD.

Read Article

Tuesday 4th August 2020

Evidence for utilising role-play workshops for the education of rare diseases

A research team based at Lille University implemented a simulation-based workshop to assess if there would be a positive change in the ability of medical students to recognise Raynaud's and scleroderma.

Read Article

Friday 17th July 2020

The crossroad between scleroderma and Covid-19

The COVID-19 pandemic continues to be, a challenging period of almost everyone’s lives. A team of researchers from the University of Florence and Shantou investigated the potential of Covid-19 complicating interstitial lung disease in scleroderma as well as the effects on routine clinical care and psychosocial implications.

Read Article

Friday 3rd July 2020

Digital Ulcers – Capturing The Patient Experience to Improve Outcomes

Researchers funded by the Scleroderma Clinicals Trials Consortium (SCTC) sought to understand how digital ulcers can affect a person’s life, discussing pain, aggravating factors and practical measures taken when ulcers develop.

Read Article

Friday 26th June 2020

New findings on lenabasum from RESOLVE-1 trial

Lenabasum is a synthetic drug that activates a certain receptor involved in the immune system and in the activity of fibroblasts, which drive fibrosis (scarring), and is particularly useful for diffuse cutaneous scleroderma.

Read Article